L32- Antihyperlipidemic Drugs Flashcards
(48 cards)
hyperlipidemia, aka (1), is defined as (2) and is associated with an increased risk for (3)
1- dyslipidemia
2- high LDL, high TGs and or low HDL
3- CVD
discuss the risk of cardiovascular mortality and hyperlipidemia
- closely linked to elevated LDL and low HDL
- elevated TGs are an independent risk factor
hyperlipidemia and _______ are risk factors for CVD
- HTN
- cigarette smoking
- obesity
- diabetes
list the primary causes for hyperlipidemia
- monogenic diseases
- genetic polymorphisms
- gene-environment interactions
Type I Hyperlipidemia disease:
(1) alternate name
(2) lipid profile
(3) etiology
1- familial hyperchylomicronemia
2- elevated CMs
3- LPL or apoCII deficiency
Type II-A Hyperlipidemia disease:
(1) alternate name
(2) lipid profile
(3) etiology
1- familial hypercholesterolemia
2- elevated LDL
3- dec or non-functional LDL receptor expression
Type II-B Hyperlipidemia disease:
(1) alternate name
(2) lipid profile
(3) etiology
1- familial combined hyperlipidemia
2- elevated VLDL, LDL
3- overproduction of VLDL in liver
Type III Hyperlipidemia disease:
(1) alternate name
(2) lipid profile
(3) etiology
1- familial dysbetalipoproteinemia
2- elevated IDL
3- abnormal apoE
Type IV Hyperlipidemia disease:
(1) alternate name
(2) lipid profile
(3) etiology
1- familial hypertriglyceridemia
2- elevated VLDL
3- overproduction and or impaired catabolism of VLDL
Type V Hyperlipidemia disease:
(1) alternate name
(2) lipid profile
(3) etiology
1- familial mixed hypertriglyceridemia
2- elevated CM, VLDL
3- inc production or dec clearance of VLDL, CMs
_____ and _____ are the most common hyperlipidemia disorders
- Type II-B, familial combined hyperlipidemia (high LDL, VLDL)
- Type IV, familial hypertriglyceridemia (high VLDL)
most hyperlipidemias stem from a (primary/secondary) cause
secondary
list some secondary causes of hypertriglyceridemia
(obviously: sedentary lifestyle, + excess dietary intake of saturated fat, cholesterol, trans FAs)
- DM
- CRF
- hypothyroidism (also => hypercholesterolemia)
- excess EtOH
- contraceptives (oral)
- β-blockers
- glucocorticoids (also => hypercholesterolemia)
list some secondary causes of hypercholesterolemia
(obviously: sedentary lifestyle, + excess dietary intake of saturated fat, cholesterol, trans FAs)
- nephrotic syndrome
- obstructive liver disease
- hypothyroidism (also => hypertriglyceridemia)
- glucocorticoids (also => hypertriglyceridemia)
list some secondary causes of hypercholesterolemia
(obviously: sedentary lifestyle, + excess dietary intake of saturated fat, cholesterol, trans FAs)
- nephrotic syndrome
- obstructive liver disease
- hypothyroidism (also => hypertriglyceridemia)
- glucocorticoids (also => hypertriglyceridemia)
list the types of Antihyperlipidemic Drugs
- HMG-CoA reductase inhibitors (statins)
- Niacin
- bile acid-binding resins
- cholesterol absorption inhibitors
list the HMG-CoA reductase inhibitors in order of potency + indicate the most efficacious drugs
[note- mainly for LDL reduction]
- rosuvastatin (also best for TGs)
- atorvastatin (also best for TGs)
- simvastatin
- pravastatin, lovastatin
- fluvastatin
HMG = (1)
3-OH-3-methylglutarate
Note- statins are HMG analogs
discuss the steps / process of Statin’s MOA
1) Statins are HMG analogs and are reversible inhibitors of HMG-CoA reductase
2) depleted intracellular supply of cholesterol (liver)
3) upregulation of LDL receptors and HMG Co-A reductase (liver)
4) improved LDL clearance from blood
what is the main effect of Statins on lipid profile
**most effective at lowering LDL
- moderate dec in plasma TGs
- small inc HDL
what are 2 major contraindications for Statin use
- pregnant Pts
- homozygotes for familial hypercholesterolemia – lack of functional LDL receptors —> dec benefit from Statins
what are the main groups prescribed Statins
- LDL >190
- DM Pts, 40-75 y/o with LDL from 70-189 (pretty much all)
- ASCVD Pts (atherosclerotic CVD)
- Pts w/o DM, w/o ASCVD and w/ LDL 70-189 with estimated 10yr risk of ASCVD of >7.5%
what are the ‘other effects’ of Statin therapy
- improve endothelial function
- dec platelet aggregation
- stabilize atherosclerotic plaques
- reduces inflammation
discuss the adverse effects of Statin therapy and how it is monitored
1) elevated aminotransferases
- no other evidence of liver toxicity
- measured baseline, then every 1-2 mos, followed by every 6-12 mos
- a 3x inc of aminotranferases is considered significant
2) myopathy / rhabdomyolysis (rare)
- myoglobinuria => lethal renal injury
- measure CKs at baseline, then after reports of muscle pain / weakness
- discontinue immediately if CKs are elevated